Terms: = Breast cancer AND NCOA2, TIF2, 10499, ENSG00000140396, NCoA-2, MGC138808 AND Treatment
12 results:
1. An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the breast.
Vranic S; Gatalica Z
Clin Breast Cancer; 2022 Jun; 22(4):e576-e585. PubMed ID: 35027319
[TBL] [Abstract] [Full Text] [Related]
2. Recurrent uterine tumors resembling ovarian sex-cord tumors with the growth regulation by estrogen in breast cancer 1-nuclear receptor coactivator 2 fusion gene: a case report and literature review.
Chang B; Bai Q; Liang L; Ge H; Yao Q
Diagn Pathol; 2020 Sep; 15(1):110. PubMed ID: 32921307
[TBL] [Abstract] [Full Text] [Related]
3. System-level responses to cisplatin in pro-apoptotic stages of breast cancer MCF-7 cell line.
Fallahi H; Godini R
Comput Biol Chem; 2019 Dec; 83():107155. PubMed ID: 31706153
[TBL] [Abstract] [Full Text] [Related]
4. NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells.
Wagner M; Koslowski M; Paret C; Schmidt M; Türeci O; Sahin U
BMC Cancer; 2013 Dec; 13():570. PubMed ID: 24304549
[TBL] [Abstract] [Full Text] [Related]
5. Nuclear EGFR as a molecular target in cancer.
Brand TM; Iida M; Luthar N; Starr MM; Huppert EJ; Wheeler DL
Radiother Oncol; 2013 Sep; 108(3):370-7. PubMed ID: 23830194
[TBL] [Abstract] [Full Text] [Related]
6. Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer.
Moi LL; Flågeng MH; Gjerde J; Madsen A; Røst TH; Gudbrandsen OA; Lien EA; Mellgren G
BMC Cancer; 2012 Jun; 12():247. PubMed ID: 22703232
[TBL] [Abstract] [Full Text] [Related]
7. Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.
Haiman CA; Garcia RR; Hsu C; Xia L; Ha H; Sheng X; Le Marchand L; Kolonel LN; Henderson BE; Stallcup MR; Greene GL; Press MF
BMC Cancer; 2009 Jan; 9():43. PubMed ID: 19183483
[TBL] [Abstract] [Full Text] [Related]
8. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator.
Madauss KP; Grygielko ET; Deng SJ; Sulpizio AC; Stanley TB; Wu C; Short SA; Thompson SK; Stewart EL; Laping NJ; Williams SP; Bray JD
Mol Endocrinol; 2007 May; 21(5):1066-81. PubMed ID: 17356170
[TBL] [Abstract] [Full Text] [Related]
9. Aryl hydrocarbon receptor-mediated transcription: ligand-dependent recruitment of estrogen receptor alpha to 2,3,7,8-tetrachlorodibenzo-p-dioxin-responsive promoters.
Matthews J; Wihlén B; Thomsen J; Gustafsson JA
Mol Cell Biol; 2005 Jul; 25(13):5317-28. PubMed ID: 15964790
[TBL] [Abstract] [Full Text] [Related]
10. The genes of the coactivator tif2 and the corepressor SMRT are primary 1alpha,25(OH)2D3 targets.
Dunlop TW; Väisänen S; Frank C; Carlberg C
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):257-60. PubMed ID: 15225781
[TBL] [Abstract] [Full Text] [Related]
11. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
[TBL] [Abstract] [Full Text] [Related]
12. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract] [Full Text] [Related]
